Report: Weak rupee hampers Indian CRO sales

CROs in India have grown accustomed to galling year-over-year growth of late, but factors like currency exchange rates and bad PR have slowed the business down over the past few months, CEOs say.

Douglas Berthiaume, CEO of Waters ($WAT), told investors that the lagging rupee has forced Indian CROs to delay spending. And Sigma-Aldrich ($SIAL) CEO Rakesh Sachdev said the Indian CRO market has come back to earth after "obscene" growth in the past, Outsourcing-Pharma reports.

But currency is hardly the only factor. March's "Dateline" report on unethical trial practices by Indian CROs has cast a wide shadow, and many pharmas remain wary of doing clinical research business in the country, one analyst told Outsourcing-Pharma. The exposé, focused on Lambda Therapeutic Research and Synchron Research Services, found the companies willing to test dangerous drugs on Indian patients while paying them fractions of normal rates.

Furthermore, the Indian government has gradually begun regulating CROs more strictly, according to ACRO's John Lewis, and this is driving some multinational pharmas to look elsewhere for their trials.

- read the Outsourcing-Pharma report

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.